(0.25%) 5 119.25 points
(0.02%) 38 734 points
(0.66%) 17 724 points
(-0.38%) $83.04
(-0.22%) $1.808
(-0.55%) $2 329.20
(-0.68%) $27.18
(-0.20%) $921.00
(0.18%) $0.936
(0.67%) $10.98
(0.17%) $0.804
(-0.82%) $92.43
Live Chart Being Loaded With Signals
Vectura Group Plc engages in the provision of pharmaceutical development. The company is headquartered in Chippenham, Wiltshire and currently employs 453 full-time employees...
Stats | |
---|---|
Today's Volume | 203 762 |
Average Volume | 8.30M |
Market Cap | 0.00 |
EPS | £-0.00834 ( 2019-06-29 ) |
Last Dividend | £19.00 ( 2021-06-01 ) |
Next Dividend | £0 ( N/A ) |
P/E | 0.0800 |
ATR14 | £0 (0.00%) |
Vectura Group PLC Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Vectura Group PLC Financials
Annual | 2020 |
Revenue: | £190.60M |
Gross Profit: | £101.40M (53.20 %) |
EPS: | £0.188 |
Q2 | 2019 |
Revenue: | £44.58M |
Gross Profit: | £23.83M (53.45 %) |
EPS: | £-0.00848 |
Q1 | 2019 |
Revenue: | £44.58M |
Gross Profit: | £23.83M (53.45 %) |
EPS: | £-0.00848 |
Q1 | 2019 |
Revenue: | £44.58M |
Gross Profit: | £23.83M (53.45 %) |
EPS: | £-0.00848 |
Financial Reports:
No articles found.
Vectura Group PLC Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
First Dividend | £6.50 | 2019-10-14 |
Last Dividend | £19.00 | 2021-06-01 |
Next Dividend | £0 | N/A |
Payout Date | 2021-06-11 | |
Next Payout Date | N/A | |
# dividends | 2 | -- |
Total Paid Out | £25.50 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.69 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 4.35 | |
Div. Directional Score | 8.24 | -- |
Year | Amount | Yield |
---|---|---|
2019 | £0 | 0.00% |
2020 | £0 | 0.00% |
2021 | £0 | 0.00% |
2022 | £0 | 0.00% |
2023 | £0 | 0.00% |
2024 | £0 | 0.00% |
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
SQZ.L | Dividend Knight | 2023-10-26 | Annually | 5 | 3.33% | |
JSG.L | Dividend Knight | 2023-10-05 | Annually | 32 | 0.64% | |
CCC.L | Dividend Knight | 2023-09-28 | Semi-Annually | 26 | 1.57% | |
POLR.L | Dividend King | 2023-07-06 | Semi-Annually | 18 | 4.22% | |
GEM.L | Dividend Knight | 2023-04-27 | Semi-Annually | 3 | 7.30% | |
ALFA.L | Dividend King | 2023-09-14 | Semi-Annually | 5 | 3.78% | |
THS.L | Dividend Knight | 2023-06-08 | Annually | 7 | 3.10% | |
LTHM.L | Dividend Knight | 2023-08-03 | Semi-Annually | 33 | 0.87% | |
CPG.L | Dividend Knight | 2023-06-08 | Annually | 24 | 0.87% | |
RKT.L | Dividend Knight | 2023-08-03 | Semi-Annually | 23 | 1.95% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.642 | 1.500 | 10.00 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.184 | 1.200 | 3.87 | 4.65 | [0 - 0.3] |
returnOnEquityTTM | 0.254 | 1.500 | 8.29 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 3.59 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 0.923 | 0.800 | 9.28 | 7.42 | [0.8 - 2.5] |
cashRatioTTM | 0.923 | 1.500 | 5.99 | 8.98 | [0.2 - 2] |
debtRatioTTM | 0.00631 | -1.500 | 9.89 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 1 314.00 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 0.0380 | 2.00 | 9.99 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0.0181 | 2.00 | 9.99 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.00771 | -1.500 | 9.97 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.532 | 1.000 | 4.47 | 4.47 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.689 | 1.000 | 10.00 | 10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 5.90 | 1.000 | 10.00 | 10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.286 | 0.800 | -1.425 | -1.140 | [0.5 - 2] |
Total Score | 12.14 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 8.78 | 1.000 | 9.21 | 0 | [1 - 100] |
returnOnEquityTTM | 0.254 | 2.50 | 8.90 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.0181 | 2.00 | 9.99 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0.0380 | 2.00 | 9.99 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0 | 1.500 | -3.33 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.130 | 1.000 | 9.25 | 0 | [0.1 - 0.5] |
Total Score | 4.35 |
Vectura Group PLC
Vectura Group Plc engages in the provision of pharmaceutical development. The company is headquartered in Chippenham, Wiltshire and currently employs 453 full-time employees. The firm's products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) - LABA-LAMA; Seebri Breezhaler (EU and RoW) - LAMA; AirFluSal Forspiro (EU and RoW) - ICS-LABA; ADVATE (Global) - Antihaemophilic Factor (Recombinant); Adept (Global) - Icodextrin; Anoro Ellipta (Global) - LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) - ICS-LABA, and Incruse Ellipta (Global) - LAMA. Its product pipeline includes VR588, VR475, VR647, VR942, VR179, VR736, VR096, VR876, VR315, VR506, VR632, Seebri Neohaler and VR465. Its dry powder inhalers (DPI) include GyroHaler, Lever-operated, Open-inhale-close and Unit Dose DPI. Its smart nebuliser delivery systems provide targeted inhalation therapy for applications where precise and targeted delivery of a drug to the lungs is needed. Its smart nebulizer delivery systems include AKITA JET and FOX.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators